XML 61 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Equity (USD $)
Total
Convertible Preferred Stock [Member]
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Parent [Member]
Noncontrolling Interest [Member]
Total NeoStem, Inc. Shareholders' Equity [Member]
Treasury Stock [Member]
Comprehensive Income [Member]
Non-Controlling Interest in Subsidiary [Member]
Beginning Balance at Dec. 31, 2010 $ 86,487,619 $ 100   $ 63,813 $ 141,137,522 $ 2,779,066 $ (95,320,620) $ 48,659,881 $ 37,827,738   $ 0    
Beginning Balance (in shares) at Dec. 31, 2010   10,000   64,221,130                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (56,582,857)           (47,134,469) (47,134,469) (9,448,388)        
Foreign currency translation 2,596,987         1,373,277   1,373,277 1,223,710        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period       5,000                  
Stock Issued During Period, Value, Stock Options Exercised 7,100     5 7,095     7,100          
Share-based compensation (in shares)       3,824,018                  
Share-based compensation 10,266,023     3,824 10,262,199     10,266,023          
Proceeds from issuance of common stock (in shares)       19,678,224                  
Proceeds from issuance of common stock 21,152,682     19,678 21,133,004     21,152,682          
Stock Issued During Period Value Charitable Contribution 607,363     408 606,955     607,363          
Repayment of Series E Preferred Principal and Dividends (in shares)       5,157,732                  
Issuance Of Common Stock In Connection With Preferred Stock Settlement Value 3,620,300     5,158 4,254,907   (639,765) 3,620,300          
Dividends (11,726,099)               (11,726,099)        
Contributions From Noncontrolling Interests 1,150,000       920,000     920,000 230,000        
Stock Issued During Period Shares PCT Merger       10,600,000                  
Stock Issued During Period Value PCT Merger 17,200,000     10,600 17,189,400     17,200,000          
Stock Issued During Period Shares Amorcyte Merger       5,843,483                  
Stock Issued During Period Value Amorcyte Merger 5,353,400     5,844 5,347,556     5,353,400          
Stock Issued During Period, Shares, Warrant Inducements 670,000                        
Ending Balance at Dec. 31, 2011 80,132,518 100   109,330 200,858,638 4,152,343 (143,094,854) 62,025,557 18,106,961   0    
Ending Balance (in shares) at Dec. 31, 2011   10,000   109,329,587                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (66,369,311)           (53,769,484)     (53,769,484)     (12,599,827)
Foreign currency translation 385,905         235,028       235,028     150,877
Share-based compensation (in shares)       3,364,268                  
Share-based compensation 6,712,536     3,364 6,709,172         6,712,536      
Proceeds from issuance of common stock (in shares)       35,732,289                  
Proceeds from issuance of common stock 16,428,827     35,732 16,393,095         16,428,827      
Repayment of Series E Preferred Principal and Dividends (in shares)       2,792,375                  
Issuance Of Common Stock In Connection With Preferred Stock Settlement Value 674,194     2,792 1,199,425   (528,023) 674,194          
Proceeds from warrant exercises (in shares)       11,076,182                  
Proceeds from warrant exercises 6,604,419     11,077 6,593,342         6,604,419      
Stock Repurchased and Retired During Period, Value (1,117,901)       452,301         (1,117,901) (665,600)    
other comprehensive income, foreign currency translation elimination on sale of segment (10,402,352)                 (4,387,371)   (4,387,371) (6,014,981)
Stock Issued During Period, Shares, Warrant Inducements 419,690     1,458,952                  
Warrant inducements (228,676)     1,459 (230,135)         (228,676)      
Ending Balance at Dec. 31, 2012 $ 32,820,159   $ 100 $ 163,754 $ 231,071,236 $ 0 $ (197,392,361)     $ 33,177,129 $ (665,600)   $ (356,970)
Ending Balance (in shares) at Dec. 31, 2012     10,000 163,753,653